ES2059121T5 - Uso de agentes sensibilizantes de la insulina para tratar la hipertension. - Google Patents

Uso de agentes sensibilizantes de la insulina para tratar la hipertension.

Info

Publication number
ES2059121T5
ES2059121T5 ES91904163T ES91904163T ES2059121T5 ES 2059121 T5 ES2059121 T5 ES 2059121T5 ES 91904163 T ES91904163 T ES 91904163T ES 91904163 T ES91904163 T ES 91904163T ES 2059121 T5 ES2059121 T5 ES 2059121T5
Authority
ES
Spain
Prior art keywords
insulin sensitizing
treat hypertension
sensitizing agents
insulin
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91904163T
Other languages
English (en)
Other versions
ES2059121T3 (es
Inventor
Jerry R Colca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23898474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2059121(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of ES2059121T3 publication Critical patent/ES2059121T3/es
Application granted granted Critical
Publication of ES2059121T5 publication Critical patent/ES2059121T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN METODO PARA EL TRATAMIENTO DE LA HIPERTENSION EN PACIENTES RESISTENTES A INSULINA QUE COMPRENDE LA ADMINISTRACION DE UN AGENTE DE SENSIBILIZACION DE INSULINA, PARTICULARMENTE CIGLITAZONA O PIOGLITAZONA.
ES91904163T 1990-02-09 1991-01-23 Uso de agentes sensibilizantes de la insulina para tratar la hipertension. Expired - Lifetime ES2059121T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47809090A 1990-02-09 1990-02-09
PCT/US1991/000348 WO1991012003A1 (en) 1990-02-09 1991-01-23 Use of insulin sensitizing agents to treat hypertension

Publications (2)

Publication Number Publication Date
ES2059121T3 ES2059121T3 (es) 1994-11-01
ES2059121T5 true ES2059121T5 (es) 2000-12-01

Family

ID=23898474

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91904163T Expired - Lifetime ES2059121T5 (es) 1990-02-09 1991-01-23 Uso de agentes sensibilizantes de la insulina para tratar la hipertension.

Country Status (12)

Country Link
EP (1) EP0514452B2 (es)
JP (1) JP3544659B2 (es)
KR (1) KR0170416B1 (es)
AT (1) ATE93138T1 (es)
AU (1) AU651571B2 (es)
CA (1) CA2071629C (es)
DE (1) DE69100282T3 (es)
DK (1) DK0514452T4 (es)
ES (1) ES2059121T5 (es)
GR (1) GR3034508T3 (es)
HK (1) HK153996A (es)
WO (1) WO1991012003A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175179A (en) * 1991-09-25 1992-12-29 Pfizer Inc. Method for treating hypertension
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
NZ330774A (en) * 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
AU2381397A (en) * 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
NZ333065A (en) * 1996-05-31 2000-05-26 Sankyo Co Treatment or prevention of autoimmune diseases using an insulin resistance improving thiazolidinedione derivative
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
AU744518B2 (en) 1996-07-01 2002-02-28 Dr. Reddy's Laboratories Limited Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6313113B1 (en) 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
AU9762798A (en) * 1997-11-12 1999-05-31 Kyoto Pharmaceutical Industries, Ltd. Novel thiazolidine compounds and medicinal utilization thereof
HK1041201A1 (zh) * 1998-11-11 2002-07-05 Smithkline Beecham Plc 貝塔激動劑和抗糖尿病製劑的配伍
PE20010580A1 (es) * 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
EP2638898A1 (en) 2012-03-16 2013-09-18 Sanovel Ilac Sanayi ve Ticaret A.S. Metformin and Pioglitazone Formulation with Different Release Profiles
EP3025707A1 (en) 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret A.S. A multilayer tablet comprising metformin and pioglitazone
TR201620309A2 (tr) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542927A (en) * 1965-08-10 1970-11-24 Pfizer Reduction of blood sugar levels with aminomethylindoles
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
JPS5522636A (en) † 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
DE3169094D1 (en) * 1980-11-20 1985-03-28 Beecham Group Plc Secondary amines
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
EP0142102B1 (en) † 1983-11-04 1987-09-23 Beecham Group Plc Tertiary amines
US4602044A (en) † 1983-12-19 1986-07-22 Eli Lilly And Company β-phenethanolamine antiobesity agents
DE3419935A1 (de) * 1984-05-28 1985-11-28 Merck Patent Gmbh, 6100 Darmstadt Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
GB8607312D0 (en) † 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
FR2611500B1 (fr) * 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use

Also Published As

Publication number Publication date
EP0514452B1 (en) 1993-08-18
ES2059121T3 (es) 1994-11-01
DK0514452T3 (da) 1993-11-29
DK0514452T4 (da) 2000-09-18
CA2071629C (en) 1997-12-30
JPH05506430A (ja) 1993-09-22
AU651571B2 (en) 1994-07-28
DE69100282T3 (de) 2001-01-11
EP0514452A1 (en) 1992-11-25
WO1991012003A1 (en) 1991-08-22
CA2071629A1 (en) 1991-08-10
EP0514452B2 (en) 2000-07-19
ATE93138T1 (de) 1993-09-15
HK153996A (en) 1996-08-16
GR3034508T3 (en) 2000-12-29
DE69100282T2 (de) 1994-01-05
KR0170416B1 (ko) 1999-02-18
AU7241691A (en) 1991-09-03
DE69100282D1 (de) 1993-09-23
JP3544659B2 (ja) 2004-07-21

Similar Documents

Publication Publication Date Title
ES2059121T3 (es) Uso de agentes sensibilizantes de insulina para tratar la hipertension.
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
SE9404196D0 (sv) New antithrombotic formulation
NO20074774L (no) Blandinger omfattende DNA-odeleggende midler og P53
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
EA200000994A1 (ru) Применение кабэрголина при лечении синдрома усталых ног
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DK0473671T3 (da) Anvendelse af sigma-receptorligander til fremstilling af et anxiolytisk middel
MX9205127A (es) Una composicion farmaceutica y un metodo para usar una combinacion de un agente uricosurico y un antagonista eaa.
LV11894A (lv) Jauni hromana un tiohromana atvasinajumi
DK0432117T3 (da) Farmaceutisk præparat til behandling af inflammation
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
ATE129712T1 (de) Substituierte pyrido-oxazine.
BR9708037A (pt) Método para o tratamento de abuso de substância
BR0015402A (pt) Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
CO5590922A2 (es) Uso de istradefilina (kw-6002) para el tratamiento de trastornos de la conducta
SE9500897D0 (sv) The pharmacological use of certain cystine derivatives
SE9101341D0 (sv) New medicinal use
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
PT1304107E (pt) Utilizacao de derivados de oxazolidininas para o tratamento da psoriase

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 514452

Country of ref document: ES